首页> 外文期刊>Mutation Research: International Journal on Mutagenesis, Chromosome Breakage and Related Subjects >A method to distinguish between the de novo induction of thymidine kinase mutants and the selection of pre-existing thymidine kinase mutants in the mouse lymphoma assay.
【24h】

A method to distinguish between the de novo induction of thymidine kinase mutants and the selection of pre-existing thymidine kinase mutants in the mouse lymphoma assay.

机译:一种在小鼠淋巴瘤试验中区分从头诱导胸苷激酶突变体和选择已存在的胸苷激酶突变体的方法。

获取原文
获取原文并翻译 | 示例
           

摘要

The mouse lymphoma assay (MLA) is the most widely used in vitro mammalian gene mutation assay. It detects various mutation events involving the thymidine kinase (Tk) gene in L5178Y/Tk+/- -3.7.2C mouse lymphoma cells. Mutants are detected using a thymidine analogue that arrests the growth of cells containing a functional Tk gene. However, there are a number of potential test chemicals that are thymidine analogues, and there is a problem when using the MLA to evaluate the mutagenicity of these chemicals. Thymidine analogues are activated by Tk before eliciting their toxicity. Therefore, any pre-existing Tk-/- mutants may avoid the toxicity of the test chemical and obtain a growth advantage over the Tk+/- cells, increasing the Tk mutant frequency (MF) in the culture via a selection mechanism. This potential mutant selection effect needs to be distinguished from de novo mutant induction in order to properly evaluate the mutagenicity of these chemicals. Here we describe a simple MLA study design that can differentiate between the selection of pre-existing mutants and de novo mutant induction. Trifluorothymidine (TFT), a thymidine analogue and the selection agent normally used in the MLA, and 4-nitroquinoline-1-oxide (4-NQO), a potent mutagen, were used to treat cells from two different Tk+/- mouse lymphoma cell cultures with different background MFs (approximately 112 and 305x10(-6)). Both agents significantly increased the Tk MFs in both the normal and high background cultures (p<0.01). In 4-NQO-treated cultures, the induced MFs (MF of treated culture-MF of control) for the cultures with different background MFs were about the same (p>0.1), while in TFT-treated cultures, they were significantly different (p<0.01). In TFT-treated cultures, the fold-increases of MF (MF of treated culture/MF of control) for the cultures with different background MFs were about the same (p>0.1), while in 4-NQO-treated cultures, they were significantly different (p<0.01). This study confirms that, when de novo mutations are induced, the induced MF is the same for cultures with normal and artificially high background MFs. In situations where the increase in MF is due solely to selection of pre-existing mutants, the "induced" MF will be a multiple of the background MF and the magnitude of the increase of the induced MF will depend upon the magnitude of the background MF. Our results demonstrate that it is possible, using this experimental design, to distinguish between chemicals acting primarily via the selection of pre-existing Tk mutants and those inducing de novo mutants in the MLA.
机译:小鼠淋巴瘤测定法(MLA)是使用最广泛的体外哺乳动物基因突变测定法。它可以检测L5178Y / Tk +/- -3.7.2C小鼠淋巴瘤细胞中涉及胸苷激酶(Tk)基因的各种突变事件。使用胸苷类似物检测突变体,该类似物可阻止含有功能性Tk基因的细胞生长。但是,有许多潜在的待测化学药品为胸苷类似物,使用MLA评估这些化学药品的致突变性时存在问题。胸苷类似物在引起毒性之前被Tk激活。因此,任何先前存在的Tk-/-突变体都可以避免测试化学品的毒性,并获得超过Tk +/-细胞的生长优势,从而通过选择机制提高培养物中Tk突变体的频率(MF)。为了正确评估这些化学物质的致突变性,需要将这种潜在的突变体选择效果与从头突变体诱导区别开。在这里,我们描述了一个简单的MLA研究设计,该设计可以区分预先存在的突变体的选择和从头突变的诱导。通常用于MLA的胸​​苷类似物三氟胸苷(TFT)和选择剂以及有效的诱变剂4-硝基喹啉-1-氧化物(4-NQO)被用于治疗两种不同的Tk +/-小鼠淋巴瘤细胞的细胞文化具有不同的背景MF(大约112和305x10(-6))。两种试剂在正常和高背景培养中均显着增加了Tk MF(p <0.01)。在4-NQO处理的培养物中,具有不同背景MF的培养物的诱导MF(处理的培养物的MF-对照的MF)大致相同(p> 0.1),而在TFT处理的培养物中,它们的诱导MF显着不同( p <0.01)。在TFT处理的培养物中,具有不同背景MF的培养物的MF倍数增加(处理的培养物的MF /对照的MF)大约相同(p> 0.1),而在4-NQO处理的培养物中,它们的差异显着(p <0.01)。这项研究证实,当诱导从头突变时,对于具有正常和人为高背景MF的培养物,诱导的MF是相同的。如果MF的增加仅是由于预先存在的突变体的选择,那么“诱导的” MF将是背景MF的倍数,并且诱导的MF的增加幅度将取决于背景MF的幅度。 。我们的结果表明,使用这种实验设计,可以区分主要通过选择预先存在的Tk突变体起作用的化学物质和在MLA中诱导从头突变的化学物质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号